The hypothesis of the EMPRESS‐MI trial was that the remodelling benefits seen with SGLT2 inhibitors in patients with established HFrEF would extend to patients at high risk of developing heart failure as a result of an acute MI complicated by left ventricular systolic dysfunction. This evidence concerns the gene SLC5A2 and myocardial infarction.